Business
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering
About this update from Phathom Pharmaceuticals, Inc.
[{"type":"image","alt":"Phathom Pharmaceuticals","displaySize":"","headline":null,"caption":"Phathom Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":87,"url":"https://media.zenfs.com/en/globenewswire.com/08e599db31de5fdce3058dc9a47e4693"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/e3Kafcw9GRLzQ8TwZztcdw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/08e599db31de5fdce3058dc9a47e4693","width":300,"height":87}},"lazy":false},{"type":"text","content":"FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering. In addition, Phathom intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of the securities offered in the public offering. There can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the offering.","length":817,"tagName":"p"},{"type":"text","content":"Phathom intends to use the net proceeds from the proposed offering for general corporate purposes, including for working capital and commercialization and research and development expenses.","length":189,"tagName":"p"},{"type":"text","content":"Guggenheim Securities and Cantor are acting as joint bookrunning managers for the proposed offering.","length":100,"tagName":"p"},{"type":"text","content":"The securities described above are being offered by Phathom pursuant to a shelf registration statement that was filed with the Securities and Exchange Commission (SEC) on January 7, 2026 and became effective automatically upon filing. The proposed offering is being made only by means of a written prospectus, including a prospectus supplement, forming a part of an effective registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC. When available, copies of the preliminary p...